



PHOTO RELEASE

ASLAN PHARMACEUTICALS COMMENCES FIRST DAY OF TRADING ON TAIPEI EXCHANGE



ASLAN Pharmaceuticals starts trading on Taipei Exchange today. ASLAN is the first foreign biotech company to be listed on the TPEX. Dr Carl Firth (third from right), CEO and Founder of ASLAN, and his senior management team at ASLAN's listing ceremony at the stock exchange in Taiwan.

Taipei, Taiwan, 1 June 2017 – ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, is pleased to announce the admission today of its ordinary shares to trading on the Taipei Exchange. ASLAN has raised a total of NT\$1 billion (US\$33 million) from the initial public offering.

Carl Firth, CEO of ASLAN Pharmaceuticals, said: *“This is a pivotal moment in ASLAN’s evolution. The success of the IPO will enable ASLAN to deliver against its development strategy and plans for growth from a position of financial strength. We look forward to our future as a quoted company with confidence.”*

ASLAN currently has a pipeline of five novel compounds and one modybodies platform, focusing on the treatment of Asia-prevalent tumours. Its lead asset, *varlitinib*, has commenced a global pivotal study in biliary tract cancer following the Investigational New Drug approval from the US Food & Drug Administration. Led by a team of highly-experienced industry veterans with a strong track record in clinical development, ASLAN has been able to generate revenues through two outlicensing deals, attract international institutional investors, and forge strong partnerships with world-leading research institutions and international biopharmaceutical companies.

Ends



Media Contacts

Chris Fang

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

E-mail: media@aslanpharma.com

Emma Thompson / Stephanie Tan

Spurwing Communications

Tel: +65 6340 7287

Email: ASLAN@spurwingcomms.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: *varlitinib* (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com

Cautionary statement

All materials and information set out herein are for reference only and whilst we make every effort to ensure accuracy and completeness, we cannot guarantee this. We make no recommendation as to the competence or suitability of persons or entities referenced herein (if any). Nothing herein constitutes an invitation or offer to invest in or deal in the securities of ASLAN. Anyone considering investment in ASLAN should refer to the information officially published the Taiwan Stock Exchange Market Observation System (MOPS). All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on such forward-looking statements, which are inherently unreliable, and you should not rely on them. Any such forward-looking statement will have been based on ASLAN's expectations, assumptions, estimates and projections about future events on the date(s) made. Actual outcomes are subject to numerous risks and uncertainties, many of which relate to factors beyond ASLAN's control, that could cause them to differ materially from those expressed in a forward-looking statement. ASLAN has no obligation to update or otherwise revise any forward-looking statements to reflect the occurrence of unanticipated events or for any other reason.